Nisa Investment Advisors
OVID icon

Nisa Investment Advisors’s Ovid Therapeutics OVID Stock Holding History

Nisa Investment Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32K Hold
2,351
– – ﹤0.01% 2576
2026
Q1 		$5.22K Hold
2,351
– – ﹤0.01% 2446
2025
Q4 		$3.83K Hold
2,351
– – ﹤0.01% 2502
2025
Q3 		$3.06K Hold
2,351
– – ﹤0.01% 2534
2025
Q2 		$776 Buy
2,351
+1,951
+488% +$588 ﹤0.01% 2786
2025
Q1 		$125 Sell
400
-1,673
-81% -$1.03K ﹤0.01% 2957
2024
Q4 		$1.94K Buy
2,073
+1,750
+542% +$1.96K ﹤0.01% 2496
2024
Q3 		$381 Buy
323
+180
+126% +$188 ﹤0.01% 2768
2024
Q2 		$110 Buy
+143
New +$398 ﹤0.01% 2872

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nisa Investment Advisors's OVID Position: Q2 2026 in Review

Nisa Investment Advisors held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 2,351 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

Nisa Investment Advisors first reported a position in OVID in Q2 2024 and has held it in 9 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Nisa Investment Advisors held 2,351 shares of Ovid Therapeutics worth $6.32K as of Q2 2026.
  • Nisa Investment Advisors left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2576 holding.
  • Nisa Investment Advisors first reported a position in Ovid Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.